Etonogestrel
- Generic Name
- Etonogestrel
- Brand Names
- Eluryng, Enilloring, Implanon, Nexplanon, Nuvaring
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28O2
- CAS Number
- 54048-10-1
- Unique Ingredient Identifier
- 304GTH6RNH
- Background
Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.
- Indication
Etonogestrel is administered in subdermal implants as long-acting reversible contraception. It is known to be effective in postpartum insertion including breastfeeding women.
Etonogestrel is part of the long-acting contraceptive implants that prevent pregnancy. The implant's effect can remain for 5 years.
- Associated Therapies
- Contraception, Contraceptive implant therapy
Body Composition and Sport Performance Among Young Female Soccer Players Using Subdermic Etonogestrel
- Conditions
- Menstrual Symptoms
- Interventions
- Device: Implanon NXT® subdermal implant
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Maíta Poli de Araújo
- Target Recruit Count
- 40
- Registration Number
- NCT06775626
- Locations
- 🇧🇷
Department of Gynecology of Federal University of São Paulo, São Paulo, Brazil
The Use of Etonogestrel Contraceptive Implant as Treatment for Endometrial Hyperplasia Without Atypia: A Cohort Study
- Conditions
- Endometrial Hyperplasia Without Atypia
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- University of the Philippines
- Target Recruit Count
- 60
- Registration Number
- NCT06378489
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
- Conditions
- Emergency Contraception
- Interventions
- Device: Etonogestrel implant with oral placebo
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Lori Gawron
- Target Recruit Count
- 790
- Registration Number
- NCT06162611
- Locations
- 🇺🇸
Planned Parenthood Association of Utah, Salt Lake City, Utah, United States
Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Target Recruit Count
- 180
- Registration Number
- NCT05791799
Endometrial Biopsy in Progestin Contraceptive Users
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 52
- Registration Number
- NCT05760144
- Locations
- 🇺🇸
OHSU, Portland, Oregon, United States
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 22
- Registration Number
- NCT05730205
- Locations
- 🇺🇸
Penn Medicine University City, Philadelphia, Pennsylvania, United States
Etonogestrel Implant as Emergency Contraception
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 12
- Registration Number
- NCT05237141
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study
- Conditions
- DysmenorrheaAbnormal Uterine Bleeding
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Saskatchewan Health Authority - Regina Area
- Target Recruit Count
- 3
- Registration Number
- NCT05227456
- Locations
- 🇨🇦
Saskatchewan Health Authority, Regina, Saskatchewan, Canada
Does Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year?
- Conditions
- ContraceptionProgestogen Adverse Reaction
- Interventions
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 67
- Registration Number
- NCT05174195
Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Registration Number
- NCT05156658
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.